진로
Dr. Sarah Lastakchi joined Malvern Panalytical in 2021. Prior to joining the company, Sarah was working in the pharmaceutical sector. She earned her Ph.D from the University of Birmingham, where she worked with Prof. Christopher McConville on finding treatment for Glioblastoma brain tumour.
During her early career, Sarah spent lots of time burdened with inefficient processes and techniques within the scientific environment. She is now committed to finding simpler ways for scientists to make discoveries.
Keep up to date with Sarah’s work: LinkedIn
전문 저널
Dr. Lastakchi has authored a number of peer-reviewed publications:
- Local administration of irinotecan using an implantable drug delivery device stops high-grade glioma tumor recurrence in a glioblastoma tumor model
- Marwick D, Lastakchi S, Barker D: EP4312016. European Patent Application; 2024
- A Potential New Treatment for High-Grade Glioma: A Study Assessing Repurposed Drug Combinations against Patient-Derived High-Grade Glioma Cells
- Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme
- The Personalisation of Glioblastoma Treatment Using Whole Exome Sequencing: A Pilot Study
- Implantable drug delivery systems
- Demo at your desk – Data Quality Guidance on Mastersizer 3000